Medicinal Chemicals & Botanical Products · A1 · CIK 1813814
Developing novel psychedelic-derived product candidates to treat brain health disorders like anxiety and depression
Comparable business profile · signals at a glance
In the 90 days to Mar 25, 2026: 3 sold $1.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Barrow RobertChief Executive Officer | Sell | 24,431 | $18.47 | $451K |
| Mar 25, 2026 | Sullivan MarkChief Legal Officer | Sell | 10,702 | $18.47 | $198K |
| Mar 25, 2026 | Karlin DanielChief Medical Officer | Sell | 8,018 | $18.47 | $148K |
| Dec 26, 2025 | Barrow RobertChief Executive Officer | Sell | 25,791 | $13.15 | $339K |
| Dec 26, 2025 | Sullivan MarkChief Legal Officer | Sell | 11,276 | $13.15 | $148K |
| Dec 26, 2025 | Karlin DanielChief Medical Officer | Sell | 5,600 | $13.15 | $74K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 2 reputable articles.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗